Tumor Progression in Hepatocellular Carcinoma May Be Mediated by p53 Mutation

Cancer Research

Volumn 53, Issue 12, 1993, Pages 2884-2887

  Adachi, Eisuke ^a   Matsumata, Takashi ^a   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; CELL SUBPOPULATION; DNA SEQUENCE; GENE MUTATION; GENETIC HETEROGENEITY; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; EXONS; GENES, P53; HUMAN; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 0027241524     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Foulds, L. The experimental study of tumor progression: a review. Cancer Res., 14: 317-339, 1954.
2. Norwell, P.C. Mechanisms of tumor progression. Cancer Res., 46: 2203-2207, 1986.
3. Heppner, G.H. Tumor heterogeneity. Cancer Res., 44: 2259-2265, 1984.
4. Nicolson. G.L. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res., 47: 1473-1487. 1987.
5. Bishop. J.M. The molecular analysis of cancer. Science (Washington D C). 235: 305-311. 1987.
6. Fearon, E.R., and Vogelstein, B.A. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767. 1990.
7. Sidransky, D., Mikkelsen, T. Schwechheimer. K., Rosenbulum, M.L., Cavenee, W., and Vogelstein, B. Clonal expansion of p. 3 mutant cells is associated with brain tumor progression. Nature (Lond.). 355: 846-847. 1992.
8. Okuda, K. Early recognition of hepatocellular carcinoma. Hepatology. 6: 729-738, 1986.
9. Kennmochi. K., Sugihara, S., and Kojiro, M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. Liver. 7; 18-26, 1987.
10. Matsuno. Y., Hirohashi, S., Furuya, S., Sakamoto, M., Mukai, K., and Shimosato, Y. Heterogeneity of proliferative activity in nodule-in-nodule lesions of small hepatocellular carcinoma. Jpn. J. Cancer Res., HI: 1137-1140, 1990.
11. Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bringner, S.H., Collins, F.S., Weston, A., Modali, R., Harris, C.C. and Vogelstein, B. Mutations in the p. 3 gene occur in diverse human tumor types. Nature (Lond.), 342: 705-708, 1989.
12. Levine, A.J., Momand, J., and Finlay, C.A. The p. 3 tumor suppressor gene. Nature (Lond.). 351: 453-456, 1991.
13. Baker, S.J., Preisinger, A.C., Jessup, J.M., Paraskeva, C., Markovitz, S., Wilson, J.K.V., Hammilton, S., and Vogelstein, B. p. 3 gene mutations occur in combination with 17p allelic deletions as late event in colorectal tumorigenesis. Cancer Res., 50: 7717-7722. 1990.
14. von Deimling, A., Eible, R.H., Ohgashi, H., Lois, D. N., von Ammon, K., Peterson, I., Kleihues, P., Chung, R.Y. Weistler. O.D., and Seizinger, B.R. p. 3 mutations are associated with 17p allelic loss in Grade II and Grade III astrocytoma. Cancer Res., 53: 2987-2990, 1992.
15. Ito, T., Seyama, T. Mizuno. T. Tsuyma N., Hayashi, T., Dohi, K., Nakamura. N., and Akiyama, M. Unique association of p. 3 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res., 52: 1369-1371. 1992.
16. Murakami. Y., Hayashi, K., Hirohashi, S., and Sekiya, T. Aberrations of the tumor suppressor p. 3 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res., 51: 5520-5525. 1991.
17. Walker. R., Dealing, S.J., Lane, D.P., and Varley, J.M. Expression of p. 3 protein in infiltrating and in-situ breast carcinomas. J. Pathol., 165: 203-211. 1991.
18. Edmondson. H.A., and Steiner, P.E. Primary carcinoma of the liver a study of 100 cases among 48, 900 necropsies. Cancer (Phila). 7: 462-503, 1954.
19. Goelz, S.E., Hamilton, S.R., and Vogelstein, B. Purification of DNA from formaldehyde-fixed and paraffin-embedded human tissues. Biochem. Biophys. Res. Com-mun., 130: 118-126, 1985.
20. Hsu, I.C. Metcalf, R.A., Sun, T., Welsh, J.A., Wang, N.J., and Harris, C.C. Mutational hotspot in the p. 3 gene in human hepatocellular carcinomas. Nature (Lond.). 350: 427-428. 1991.
21. Mitsudomi, T., Steinberg, S.M., Nau, M.M., Carbone, D., D'Amico. D., Bodner, S., Oie, H.K., Linnonlia, R.I., Mulshine, J.L., Minna, J.D., and Gadzer, A.F. p. 3 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene, 7; 171-180, 1992.
22. Orita, M., Ishihara, H., Kanazawa, H., Hayashi, H., and Sekiya, T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. USA, 86: 2766-2770. 1989.
23. Tanaka, S., Ton, Y., and Mori, R. Molecular analysis of a neurovirulent herpes simplex virus type 2 strain with reduced thymidine kinase activity. Arch. Virol., in press. 1993.
24. Bressac. B., Kew, M., Wands, J., and Ozturk, M. Selective G to T mutations of p. 3 gene in hepatocellular carcinoma from southern Africa Nature (Lond.). 350: 429-431, 1991.
25. Osturk, M. p. 3 mutations in hepatocellular carcinoma after aflatoxin exposure. Lancet. 30: 1356-1359, 1991.
26. Zukut-Houri. R., Bienz-Tadmor. B., Givol, D., and Oren, M. Human p. 3 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J., 4: 1251-1255, 1985.
27. Schnipper. L.E. Clinical implications of tumor-cell heterogeneity. N. Engl. J. Med., 314: 1423-1431, 1986.
28. Ikeda K., Saitoh, S., Tsubota, A., Arase. Y., Chayama, K., Kumada, H., Watanabe, G., and Tsurumaru, M. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer (Phila.). 71: 19-25. 1993.
29. Sugihara. S., Nakashima, O., Kojiro, M., Majima, Y. Tanaka. M., and Tanigawa, K. The morphologic transition in hepatocellular carcinoma. Cancer (Phila.). 70: 1488-1492. 1992.
30. Majima. Y. Growth rate of hepatocellular carcinoma by ultrasonography and its clinical significance. Acta Hepatol. Jpn., 25: 754-765. 1984.
31. Finlay. C.A., Hinds, P.W., and Levine, A.J. The p. 3 protooncogene can act as a suppressor of transformation. Cell. 57: 1083-1093. 1989.
32. Hinds. P., Finlay. C., and Levine, A.J. Mutation is required to activate the p. 3 gene for cooperation with the ras oncogene and transformation. J. Virol., 63: 739-746. 1989.
33. Parada. L.R., Land, H., Weinberg, R.A., Wolf, D., and Rotter, V. Cooperation between genes encoding p. 3 tumor antigen and ras in cellular transformation. Nature (Lond.). 312: 649-651. 1984.
34. Rovinski, B., and Benchimol, S. Immortalization of rat embryo fibroblasts by the cellular p. 3 oncogene. Oncogene. 2: 445-452, 1988.
35. Milner. J., and Mendcalf, E.A. Cotranslation of activated mutant p. 3 with wild-type drives the wild-type p. 3 protein into the mutant conformation. Cell, 65: 765-774, 1991.
36. Halvey, O., Michalovitz, D., and Oren, M. Different tumor-derived p. 3 mutants exhibit distinct biological activities. Science (Washington D C), 250: 113-116. 1990.
37. Bischoff. J.R., Casso, D., and Beach, D. Human p. 3 inhibits growth in Schizosaechatomyces pombe. Mol. Cell. Biol., 12: 1405-1411, 1992.